Zobrazeno 1 - 10
of 19
pro vyhledávání: '"T Iu, Semiglazova"'
Autor:
V S Andrianova, A V Beliaeva, L V Bolotina, A A Vazhenina, S E Varlamova, V I Vladimirov, L Yu Vladimirova, E K Voznyi, S M Demidov, N V Zhukov, L G Zhukova, E N Imianitov, E I Kovalenko, L M Kogoniia, M M Konstantinova, S A Lan, M R Lichinitser, L V Manziuk, A G Manikhas, G Z Mukhametshina, V F Semiglazov, T Iu Semiglazova, G V Seregina, D L Stroiakovskii, M D Ter-Ovanesov, A S Chichkanova
Publikováno v:
Современная онкология, Vol 17, Iss 1, Pp 5-8 (2015)
Externí odkaz:
https://doaj.org/article/33bc649b658a4dcb99baaaeec45bafe0
Publikováno v:
Voprosy onkologii. 60(4)
Michael Lazarevich Gershanovich was born 90 years ago. He has made a significant contribution to foundation and development of chemotherapy for malignant tumors. Doctor of Medical Sciences, Professor, Laureate of the State Prize of the Russian Federa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1e9d1f0e0541dec270b8d6ea61c9d3fc
https://pubmed.ncbi.nlm.nih.gov/25552077
https://pubmed.ncbi.nlm.nih.gov/25552077
Autor:
V F, Semiglazov, V V, Semiglazov, P M, Paltuev, G A, Dashian, R V, Donskikh, A V, Komiakhov, P V, Krivorot'ko, K S, Nikolaev, I V, Nikitina, T Iu, Semiglazova
Publikováno v:
Voprosy onkologii. 60(1)
A decision regarding adjuvant chemotherapy in early (operable) breast cancer in the past was made entirely on the basis of clinical and pathological features. However with the growing awareness of tumor biology and the possibility of the genomic anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::875724f15763cf6a93f0eeb599c5dbb8
https://pubmed.ncbi.nlm.nih.gov/24772626
https://pubmed.ncbi.nlm.nih.gov/24772626
Autor:
V F, Semiglazov, A A, Bozhok, T Iu, Semiglazova, A G, Vasil'ev, A G, Manikhas, V V, Semiglazov, A A, Bessonov, K S, Nikolaev
Publikováno v:
Voprosy onkologii. 59(3)
Neoadjuvant systemic therapy is frequently used option for the systemic treatment for breast cancer. Inclusion in the regimen of targeted drugs as trastuzumab (Herceptin) and pertuzumab significantly improves outcomes in HER2-positive breast cancer p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8724f389defc9c8feef86cee0d300dda
https://pubmed.ncbi.nlm.nih.gov/23909035
https://pubmed.ncbi.nlm.nih.gov/23909035
Publikováno v:
Voprosy onkologii. 59(3)
The study presents data on the treatment of lobular breast cancer. On the basis of the studied morphological and molecular-biological characteristics there were substantiated types of treatment that improved the survival of patients with invasive lob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0e2054a0eb7f968566002b8b91bf2dad
https://pubmed.ncbi.nlm.nih.gov/23909043
https://pubmed.ncbi.nlm.nih.gov/23909043
Publikováno v:
Voprosy onkologii. 59(2)
In a retrospective study during the primary mode MOPP to primary patients LH II/IVAB stages with a poor prognosis rate of CR, 5--and 10-year DFS, OS was 69%, 71% and 68%, 74% and 64%, ABVD--76%, 78%, 83% and 68%, BEACOPP-baseline--73%, 97%, 85% and 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::155d8c44128ba09eb2b3b4648b402745
https://pubmed.ncbi.nlm.nih.gov/23814851
https://pubmed.ncbi.nlm.nih.gov/23814851
Publikováno v:
Voprosy onkologii. 58(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8314487d0d47145e1b025ef4058e6bdf
https://pubmed.ncbi.nlm.nih.gov/23607197
https://pubmed.ncbi.nlm.nih.gov/23607197
Publikováno v:
Voprosy onkologii. 58(5)
Retrospective analysis defined risk factors of primary-refractory course of Hodgkin's lymphoma as well as adverse prognostic factors, efficacy of I and II therapy lines in patients with primary-refractory forms of Hodgkin's lymphoma. By means of disc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9a43fa73b4579978f59418fe45c41b7d
https://pubmed.ncbi.nlm.nih.gov/23600279
https://pubmed.ncbi.nlm.nih.gov/23600279
Autor:
A N, Stukov, L V, Filatova, M L, Gershanovich, T Iu, Semiglazova, A A, Tarasenkova, D Kh, Latinova, S F, Vershinina, N I, Zargarova
Publikováno v:
Voprosy onkologii. 58(3)
SHR mice with intracranial transplanted lymphosarcoma LIO-1 received a single intraperitoneal gemcitabine injection in maximal tolerated dose of 25 mg/kg or single maximal tolerated oral dose of lomustine, 50 mg/kg. Compared to control group gemcitab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e20143bf6abb0a44992d61f5160d2aa4
https://pubmed.ncbi.nlm.nih.gov/22888657
https://pubmed.ncbi.nlm.nih.gov/22888657
Autor:
D Kh, Latipova, M L, Gershanovich, A N, Stukov, T Iu, Semiglazova, L V, Filatova, A A, Tarasenkova, S F, Vershinina, S A, Kon'kov, I M, Krylova, V G, Bespalov, A V, Panchenko, Ia G, Murazov
Publikováno v:
Voprosy onkologii. 57(6)
Antitumor activity of a new cytostatic drug combination of gemcitabine and dioxadet have been studied in 86 female SHR mice transplanted with 5 x 10(6) of ascitic Ehrlich's tumor cells each. All mice received a single injection of gemcitabine, dioxad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6abfd601126d1c30c4f677fcbca7d841
https://pubmed.ncbi.nlm.nih.gov/22416395
https://pubmed.ncbi.nlm.nih.gov/22416395